Original Publication Date: 1 August, 2016
Publication / Source: Future Oncology
Authors: Wojciech Rogowski, Ewa Wachuła, Anna Lewczuk et al
Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response.